secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001528287-24-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace reports record 2023 revenue $65.4M (+44% YoY); guides 2024 revenue $73M-$77M
--------------------------------------------------------------------------------

- Record FY 2023 revenue $65.4M (+44% YoY); Q4 revenue $18.0M (+41% YoY). Net loss improved to $33.0M from $47.1M.
- Gross margin improved to 73.6% (FY) from 71.4%; Q4 75.2% vs 68.8%. Cash burn reduced to $3.4M in Q4.
- FY 2024 guidance: revenue $73M-$77M (+12-18%), gross margin 72-74%, operating expenses $80M-$84M.
- NAUTILUS study for generalized epilepsy completed enrollment and implants for FDA submission; Project CARE pilot initiated.
- Cash position $66.5M, long-term debt $57.0M; stock-based comp ~$9.6M in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828724000004/0001528287-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828724000004/npce-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001528287-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer